The relationship between metabolic control and basal ganglia morphometry and function in individuals with early-treated phenylketonuria
- PMID: 36209659
- DOI: 10.1016/j.ymgme.2022.09.006
The relationship between metabolic control and basal ganglia morphometry and function in individuals with early-treated phenylketonuria
Abstract
Abnormalities of the cortical white matter are the most prominent and widely-reported neurological findings in individuals with early-treated phenylketonuria (ETPKU). Much less is known regarding the effects of ETPKU on gray matter structures in the brain such as the basal ganglia. Previous findings on basal ganglia in ETPKU have been mixed. The current study was designed to further elucidate the effects of ETPKU and elevated phe levels on the morphometry of basal ganglia structures (i.e., putamen, caudate nucleus, nucleus accumbens, and globus pallidus). High resolution magnetic resonance imaging (MRI) data was collected from a sample of 37 adults with ETPKU and a demographically-matched comparison group of 33 individuals without PKU. No overall group differences (ETPKU vs. non-PKU) in basal ganglia volumes were observed. However, within the ETPKU group, poorer metabolic control (as reflected by higher blood phenylalanine levels) was associated with larger putamen volume. Vertex-wise shape analysis revealed that the volume increase was accompanied by shape changes in the middle left putamen. Consistent with this area's role in motor control, a significant correlation between left putamen volume and motor performance was also observed. Additional research is needed to fully understand the cellular level processes underlying this effect as well as to better understand the clinical impact of these morphometric changes and their potential relation to treatment response.
Keywords: Basal ganglia; Magnetic resonance imaging; Motor ability; Phenylalanine; Phenylketonuria; Putamen.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest S.E.C. has served as a consultant for BioMarin Pharmaceutical and Synologic Therapeutics. BioMarin has also funded past research in our laboratory. A.A.B., H.E.C., E.E.A., & M.U. reported no biomedical financial interests or potential conflicts of interest. The authors confirm independence from the aforementioned entities; the content of the article has not been influenced by the entities.
Similar articles
-
A volumetric study of basal ganglia structures in individuals with early-treated phenylketonuria.Mol Genet Metab. 2012 Nov;107(3):302-7. doi: 10.1016/j.ymgme.2012.08.007. Epub 2012 Aug 18. Mol Genet Metab. 2012. PMID: 23006929
-
The effects of early-treated phenylketonuria on volumetric measures of the cerebellum.Mol Genet Metab Rep. 2020 Sep 18;25:100647. doi: 10.1016/j.ymgmr.2020.100647. eCollection 2020 Dec. Mol Genet Metab Rep. 2020. PMID: 32995290 Free PMC article.
-
Neuropsychological assessment of adults with phenylketonuria using the NIH toolbox.Mol Genet Metab. 2023 May;139(1):107579. doi: 10.1016/j.ymgme.2023.107579. Epub 2023 Apr 8. Mol Genet Metab. 2023. PMID: 37099821
-
The basal ganglia and apraxia.Brain. 1996 Feb;119 ( Pt 1):319-40. doi: 10.1093/brain/119.1.319. Brain. 1996. PMID: 8624692 Review.
-
The neurological and psychological phenotype of adult patients with early-treated phenylketonuria: A systematic review.J Inherit Metab Dis. 2019 Mar;42(2):209-219. doi: 10.1002/jimd.12065. J Inherit Metab Dis. 2019. PMID: 30690773
Cited by
-
Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels.J Neurodev Disord. 2024 Jun 21;16(1):33. doi: 10.1186/s11689-024-09553-w. J Neurodev Disord. 2024. PMID: 38907189 Free PMC article.
-
Total choline intake and working memory performance in adults with phenylketonuria.Orphanet J Rare Dis. 2023 Jul 29;18(1):222. doi: 10.1186/s13023-023-02842-y. Orphanet J Rare Dis. 2023. PMID: 37516884 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical